- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05956158
RISE: A Remote Study of Insomnia Treatment in Crohn's Disease (RISE)
January 12, 2024 updated by: Jessica.K.Salwen-Deremer, Dartmouth-Hitchcock Medical Center
The purpose of this study is to assess whether the investigators can treat insomnia in people with Crohn's disease, and if insomnia treatment can make other things better, like pain or inflammation.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
People with Crohn's disease often suffer from sleep problems.
Long term, sleep problems may lead to more flares of Crohn's disease or other complications.
In general, patients with Crohn's disease also report that sleep problems can worsen symptoms of Crohn's disease the next day.
In people with other medical problems, research has also shown that having sleep problems can make other things worse, such as pain and inflammation.
In this study, the investigators want to understand if they can treat sleep problems in people with Crohn's disease, and what else might improve if sleep gets better.
If this study is successful, it will help the investigators understand more about how to treat insomnia in people with Crohn's disease and how sleep impacts pain and inflammation.
Long term, this information will be helpful in understanding how best to take care of people with Crohn's disease.
Study Type
Interventional
Enrollment (Estimated)
83
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New Hampshire
-
Lebanon, New Hampshire, United States, 03756
- Recruiting
- Dartmouth-Hitchcock Medical Center
-
Contact:
- Jessica K Salwen-Deremer, PhD
- Phone Number: 603-650-6388
- Email: jessica.k.salwen-deremer@hitchcock.org
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Mild to moderate CD based on PRO-3 & objective data
- Insomnia Severity Index score ≥ 8 and SOL or WASO ≥ 30 minutes
- Stability of sleep & CD meds for ≥ 3 months
- Access to internet or cell phone service sufficient for telehealth
Exclusion Criteria:
- PHQ-9 depression score ≥ 15
- GAD-7 anxiety score ≥ 15
- Unstable major psychiatric condition (e.g., bipolar disorder, psychotic disorder)
- Current alcohol or substance abuse
- Current opioid use for pain control
- Current smoker (tobacco, nicotine)
- Current systemic corticosteroid use
- Current pregnancy or nursing
- Ileostomy or colostomy
- Diagnosis of seizure disorder
- Diagnosis of sleep apnea or positive WatchPAT screen
- Diagnosis of restless leg syndrome or positive Cambridge-Hopkins RSLq screen
- Night shift, rotating shift work, or frequent travel outside of time zone
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Behavioral Treatment
|
This treatment is designed to help participants make changes to behavior patterns and thoughts that contribute to insomnia.
Other Names:
|
Placebo Comparator: Sleep Education Treatment
|
This treatment is designed to help participants understand the relationships among sleep, pain, and Crohn's disease and to make changes to insomnia-related behaviors.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Feasibility of the intervention as measured by attrition rate over time
Time Frame: Baseline, 8 weeks, 21 weeks, and 34 weeks
|
Attrition rate will be based on the percentage of participants who have dropped out of the trial at different time points.
|
Baseline, 8 weeks, 21 weeks, and 34 weeks
|
Feasibility of the intervention as measured by recruitment rate over time
Time Frame: From study initiation until we are no longer actively recruiting (approximately 24 months)
|
Recruitment rate will be based on the number of participants who are recruited into the trial per month.
|
From study initiation until we are no longer actively recruiting (approximately 24 months)
|
Feasibility of the intervention as measured by assessment completion at multiple time points
Time Frame: Baseline, 8 weeks, 21 weeks, and 34 weeks
|
Assessment completion rate will be based on the percentage of participants who complete all the required questionnaires and tasks at each time point.
|
Baseline, 8 weeks, 21 weeks, and 34 weeks
|
Feasibility of the intervention as measured by qualitative interviews
Time Frame: 8 weeks and 34 weeks
|
Feasibility will be based on interview-derived themes related to barriers and facilitators to study engagement.
Data will be collected at two time points to ensure completeness of themes.
|
8 weeks and 34 weeks
|
Acceptability of the intervention as measured by visit completion
Time Frame: 8 weeks
|
Visit completion will be based the number of visits (out of 5) completed by each participant.
|
8 weeks
|
Treatment acceptability questionnaire score
Time Frame: 1 week
|
The Treatment Acceptability Questionnaire is a 4-item self-report questionnaire designed to assess the overall acceptability of an intervention.
Scores range from 1 to 4 and higher scores are indicative of greater acceptability.
|
1 week
|
Acceptability of the intervention as measured by qualitative interviews
Time Frame: 8 weeks
|
Acceptability will be based on interview-derived themes related to aspects of the intervention that participants found helpful and unhelpful.
|
8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in insomnia symptoms as measured by the Insomnia Severity Index
Time Frame: Baseline, 8 weeks, 21 weeks, and 34 weeks
|
The Insomnia Severity Index (ISI) is a self-report questionnaire designed to measure severity of insomnia.
The ISI is made up of 7 items on insomnia symptoms and related impairments and total scores range from 0-28.
Higher scores are indicative of greater insomnia symptoms.
|
Baseline, 8 weeks, 21 weeks, and 34 weeks
|
Change in diary-based sleep onset latency
Time Frame: Baseline, 8 weeks, 21 weeks, and 34 weeks
|
A weekly average of self-reported time it takes to fall asleep each night, derived from a self-reported sleep diary
|
Baseline, 8 weeks, 21 weeks, and 34 weeks
|
Change in diary-based wake after sleep onset
Time Frame: Baseline, 8 weeks, 21 weeks, and 34 weeks
|
A weekly average of self-reported time spent awake in the middle of each night, derived from a self-reported sleep diary
|
Baseline, 8 weeks, 21 weeks, and 34 weeks
|
Change in Crohn's disease symptoms as measured by the Patient Reported Outcomes 3
Time Frame: Baseline, 8 weeks, 21 weeks, and 34 weeks
|
The Patient Reported Outcomes 3 (PRO-3) is a self-report questionnaire designed to measure the severity of Crohn's disease symptoms in the past week.
The PRO-3 is made up of 3 items (stool frequency, pain, and well-being) and higher scores are indicative of more severe symptoms.
Scores are interpreted as follows: <13=quiescent or inactive disease; 13-21=mildly active disease; 22-52=moderately active disease; 53 and up=severely active disease.
|
Baseline, 8 weeks, 21 weeks, and 34 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in C-reactive protein
Time Frame: Baseline, 8 weeks, and 21 weeks
|
We will measure blood levels of C-reactive protein
|
Baseline, 8 weeks, and 21 weeks
|
Change in fecal calprotectin
Time Frame: Baseline, 8 weeks, and 21 weeks
|
We will measure levels of fecal calprotectin via a stool sample.
|
Baseline, 8 weeks, and 21 weeks
|
Change in sleep architecture
Time Frame: Baseline, 8 weeks, and 21 weeks
|
We will measure changes in percent time spent in light sleep, deep sleep, and rapid eye movement (REM) sleep using the Oura ring.
|
Baseline, 8 weeks, and 21 weeks
|
Change in behaviorally assessed pain tolerance via the Cold Pressor Test
Time Frame: Baseline, 8 weeks, and 21 weeks
|
The Cold Pressor Test involves submerging one's non-dominant hand in ice water and rating discomfort at regular, pre-determined intervals.
Pain tolerance will be measured based on the total amount of time a participant can keep their hand submerged, with a maximum of 3 minutes.
|
Baseline, 8 weeks, and 21 weeks
|
Change in diary-based sleep efficiency
Time Frame: Baseline, 8 weeks, 21 weeks, and 34 weeks
|
Change in sleep efficiency (total sleep time / time in bed), derived from a self-reported sleep diary.
|
Baseline, 8 weeks, 21 weeks, and 34 weeks
|
Change in objective sleep onset latency
Time Frame: Baseline, 8 weeks, and 21 weeks
|
Change in the time it takes to fall asleep each night, derived from the Oura ring.
|
Baseline, 8 weeks, and 21 weeks
|
Change in objective wake after sleep onset
Time Frame: Baseline, 8 weeks, and 21 weeks
|
Change in the time spent awake in the middle of the night, derived from the Oura ring.
|
Baseline, 8 weeks, and 21 weeks
|
Change in objective sleep efficiency
Time Frame: Baseline, 8 weeks, and 21 weeks
|
Change in sleep efficiency (total sleep time / time in bed), derived from the Oura ring.
|
Baseline, 8 weeks, and 21 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 28, 2023
Primary Completion (Estimated)
November 15, 2025
Study Completion (Estimated)
May 15, 2026
Study Registration Dates
First Submitted
June 22, 2023
First Submitted That Met QC Criteria
July 13, 2023
First Posted (Actual)
July 21, 2023
Study Record Updates
Last Update Posted (Actual)
January 17, 2024
Last Update Submitted That Met QC Criteria
January 12, 2024
Last Verified
January 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- STUDY02001855
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Insomnia
-
Leiden UniversityBioClock Consortium; Caring UniveristiesCompleted
-
National Science Council, TaiwanCompleted
-
Sunshine Lake Pharma Co., Ltd.Unknown
-
Pfizer's Upjohn has merged with Mylan to form Viatris...Completed
-
Massachusetts General HospitalNational Institutes of Health (NIH)Completed
-
IpsenCompletedThe Effectiveness of Circadin in Improving Quality of Sleep in Patients Aged 55 or Over (QUALISLEEP)InsomniaRussian Federation
-
Charite University, Berlin, GermanyCompleted
-
Roxane LaboratoriesCompleted
-
Butler HospitalSunovionCompleted
Clinical Trials on Behavioral Treatment
-
University of UtahNational Institute on Drug Abuse (NIDA)Completed
-
National Institute of Diabetes and Digestive and...Completed
-
Drexel UniversityRecruitingObesity | Weight LossUnited States
-
Drexel UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)RecruitingObesity | Weight LossUnited States
-
The Miriam HospitalNational Heart, Lung, and Blood Institute (NHLBI)Completed
-
The Miriam HospitalNational Heart, Lung, and Blood Institute (NHLBI)Unknown
-
Becky MarquezRecruiting
-
The Miriam HospitalCompleted
-
New York State Psychiatric InstituteNational Institute of Mental Health (NIMH)CompletedEating DisordersUnited States
-
Ananias DioknoNational Institute on Aging (NIA)CompletedUrinary Incontinence, Stress | Urinary Incontinence, UrgeUnited States